When was Altor Bioscience founded?

Altor Bioscience was founded in 2002 and raised its 1st funding round within a year of its incorporation.

Where is Altor Bioscience located?

Altor Bioscience is headquartered in United States.

Who is the current CEO of Altor Bioscience?

Hing Wong of Altor Bioscience. They have also founded 1 company.

Is Altor Bioscience a funded company?

Altor Bioscience is a funded company, having raised a total of $92.7M across 27 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 26, 2002.

When was the latest funding round of Altor Bioscience?

Altor Bioscience's latest funding was a $***** Grant (prize money) round on Sep 30, 2018, with participation from 1 investor. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $601M in funding in 2026 to date.

Where does Altor Bioscience rank among its competitors?

Altor Bioscience ranks 55th amongst 316 active competitors, of which 85 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Leyden Labs, which secured $45.5M in Jun, 2026.

Who are the top competitors of Altor Bioscience?

Altor Bioscience's top competitors include Dynavax, HOOKIPA Pharma and Vaxart. Among them, Leyden Labs secured the most recent funding round in June, 2026.

Altor Bioscience - 2026 Company Profile, Team, Funding & Competitors

Q: Is Altor Bioscience an acquired company?

Altor Bioscience got acquired by NantHealth on Jun 27, 2017.

Company Details

Developer of immunotherapeutics for the treatment of various diseases. The company is developing cell and immunotherapy products for the treatment of cancer and infectious diseases. The product pipeline includes Anktiva for the treatment of bladder and lung cancer.

Website: altorbioscience.com
Social

Key Metrics

Founded Year

2002

Location

United States

Stage

Acquired

Total Funding

$92.7M in 27 rounds

Latest Funding Round

Grant (prize money), Sep 30, 2018, $*****

Investors

Sanderling Ventures & 5 more

Ranked

55^th among 316 active competitors

Similar Companies

Dynavax & 384 more

Exit Details

Acquired by NantHealth (Jun 27, 2017)

View Altor Bioscience's full profile

Altor Bioscience got acquired by NantHealth on Jun 27, 2017 at an acquisition amount of $*****.

Click here to take a look at Altor Bioscience's acquisition in detail

Altor Bioscience has raised a total funding of $92.7M over 27 rounds. Its first funding round was on Jul 26, 2002. Its latest funding round was a Grant (prize money) round on Sep 30, 2018 for $*****. 1 investor participated in its latest round. Altor Bioscience has 6 institutional investors.

Here is the list of recent funding rounds of Altor Bioscience:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 30, 2018	9562248	Grant (prize money)	6200003	2030289	8428500	4957950
Mar 22, 2017	3726612	Series G	5107723	3118297	5805409	2619937
Jul 19, 2016	5654383	Series F	1580179	5442986	8602055	7751431

Access funding benchmarks and valuations. Sign up today!

View details of Altor Bioscience's funding rounds and investors

The founders of Altor Bioscience is Hing Wong. Hing Wong is the CEO of Altor Bioscience.

Here are the details of Altor Bioscience's key team members:

Hing Wong: Founder & CEO of Altor Bioscience and founder of 1 other company.
Contact Info: 2 email addresses

View details of Altor Bioscience's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Altor Bioscience include Dynavax, HOOKIPA Pharma and Vaxart. Here is the list of Top 10 competitors of Altor Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Dynavax 1996, Berkeley (United States), Acquired	Developer of products to prevent and treat infectious and inflammatory diseases and cancer	$73.9M	Care Capital, Axiom Venture Partners & 27 others	70/100
2nd	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	70/100
3rd	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	67/100
4th	Atea 2014, Boston (United States), Public	Developer of therapeutics for viral diseases	$293M	GSA Capital Partners, Bain Capital & 18 others	67/100
5th	Leyden Labs 2020, Leiden (Netherlands), Series B	Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa	$303M	Google Ventures, Clavystbio & 14 others	64/100
6th	Sinovac 2001, Haidian (China), Acquired	Developer of vaccines against multiple infectious diseases	-	Sino Biopharmaceutical, Vivo Capital & 3 others	64/100
7th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Boyu Capital & 7 others	63/100
8th	eradivir 2020, West Lafayette (United States), Series A	Developer of immunotherapies for the treatment of infectious diseases	$20.4M	Research Bridge Partners, HHS & 2 others	62/100
9th	Virica Biotech 2018, Ottawa (Canada), Series A	Developer of viral sensitizer technology therapeutics to treat viral infections	$11.6M	Dynamk Capital, AyaWas Group & 4 others	60/100
10th	Novan 2006, Morrisville (United States), Public	Developer of Nitric Oxide based therapeutics for dermatology disorders	$113M	Aspire Capital, Ligand Pharmaceuticals & 6 others	60/100
55th	Altor Bioscience 2002, United States, Acquired	Developer of immunotherapeutics for the treatment of various diseases	$92.7M	HHS, National Cancer Institute & 4 others	49/100